- Home
- CSBR vs BDTX Comparison
CSBR vs BDTX Comparison
Compare CSBR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- BDTX
- Stock Information
- Founded
- CSBR 1985
- BDTX 2014
- Country
- CSBR United States
- BDTX United States
- Employees
- CSBR N/A
- BDTX N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSBR Health Care
- BDTX Health Care
- Exchange
- CSBR Nasdaq
- BDTX Nasdaq
- Market Cap
- CSBR 111.4M
- BDTX 132.5M
- IPO Year
- CSBR 1986
- BDTX 2020
- Fundamental
- Price
- CSBR $8.33
- BDTX $2.87
- Analyst Decision
- CSBR Strong Buy
- BDTX Strong Buy
- Analyst Count
- CSBR 1
- BDTX 6
- Target Price
- CSBR $12.00
- BDTX $14.83
- AVG Volume (30 Days)
- CSBR 39.6K
- BDTX 1.2M
- Earning Date
- CSBR 09-10-2025
- BDTX 08-05-2025
- Dividend Yield
- CSBR N/A
- BDTX N/A
- EPS Growth
- CSBR N/A
- BDTX N/A
- EPS
- CSBR 0.46
- BDTX 0.09
- Revenue
- CSBR $58,591,000.00
- BDTX $70,000,000.00
- Revenue This Year
- CSBR $15.11
- BDTX N/A
- Revenue Next Year
- CSBR $7.80
- BDTX N/A
- P/E Ratio
- CSBR $17.71
- BDTX $32.58
- Revenue Growth
- CSBR 19.03
- BDTX N/A
- 52 Week Low
- CSBR $3.60
- BDTX $1.20
- 52 Week High
- CSBR $11.99
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- CSBR 64.00
- BDTX 68.91
- Support Level
- CSBR $7.16
- BDTX $2.43
- Resistance Level
- CSBR $9.63
- BDTX $2.72
- Average True Range (ATR)
- CSBR 0.64
- BDTX 0.18
- MACD
- CSBR 0.11
- BDTX 0.02
- Stochastic Oscillator
- CSBR 69.06
- BDTX 99.31
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.